Frontiers in Pharmacology

Original Research

Published on 19 Sep 2025

Rational design of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors featuring 1,2,3-triazole derivatives with enhanced anti-inflammatory and analgesic efficacy

in Neuropharmacology

Qingying Liu
Xixi Hou
Yueliang Wang
Mingyue Tian
Baoyu He
Jingjing Guo
Jianxue Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1574007

181 views

Brief Research Report

Published on 19 Sep 2025

Single-versus multiple-inhaler triple therapy in patients with COPD in Spain: a retrospective cohort study comparing adherence, persistence, risk of exacerbations and economic outcomes

in Pharmacoepidemiology

M. Asunción González-González
M. Aránzazu Pedrosa-Naudín
Diego Fernández-Lázaro
Isabel Díaz Planelles
F. Javier Álvarez
Eduardo Gutiérrez-Abejón

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1642470

702 views

Review

Published on 19 Sep 2025

ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases

in Experimental Pharmacology and Drug Discovery

Lisa Liu
Erkang Tian
Shuqi Quan
Chongying Su
Jiawei Zhou
Sijia Hu
Nanyan Bian
Shufang Du
Juan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1640090

258 views

Review

Published on 19 Sep 2025

Research progress on plant-derived natural compounds regulating the MAPK signaling pathway for the prevention and therapy of Alzheimer’s disease

in Neuropharmacology

Xinyue Zhang
Shujia Huang
Hongfeng Xu
Yanan Hu
Ling Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1666082

202 views

Systematic Review

Published on 19 Sep 2025

Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis

in Gastrointestinal and Hepatic Pharmacology

Xingmiao Xie
Shuiyuan Yang
Shuzhen Deng
Yuying Liu
Zhibin Xu
Binghong He

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1613610

314 views

Original Research

Published on 19 Sep 2025

Comprehensive chemical profiling and human health risk assessment of potentially toxic heavy metals in some traditional herbal concoctions from Botswana

in Ethnopharmacology

Ontlametse H. E. Phiri
Lucia M. Lepodise
Tshepo Pheko-Ofitlhile

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1652817

Original Research

Published on 19 Sep 2025

Exploration of the role of Fomitopsis officinalis Ames in the treatment of gastric cancer using network pharmacology, molecular docking, and in vitro experiments

in Ethnopharmacology

Xue Guan
Dazhong Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1656365

176 views

Original Research

Published on 19 Sep 2025

Exploring the top 30 drugs associated with drug-induced thrombotic microangiopathy based on the FDA adverse event reporting system

in Pharmacology of Anti-Cancer Drugs

Yi Yin
Fanmin Meng
Yanjiao Fan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1658963

247 views

Original Research

Published on 19 Sep 2025

Multidisciplinary administrative-professional-technical interventions to optimize antibiotic use and reduce resistance in a tertiary general hospital

in Drugs Outcomes Research and Policies

Jingjing Han
Meiyu Shen
Yan Rao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1592158

113 views

Original Research

Published on 19 Sep 2025

Prevalence of risk phenotypes associated with CYP2C92, 3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice

in Pharmacogenetics and Pharmacogenomics

Mohitosh Biswas
Murshadul Alam Murad
Maliheh Ershadian
Most. Sumaiya Khatun Kali
Maw Shin Sim
Baharudin Ibrahim
Chonlaphat Sukasem

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1597379

235 views

Original Research

Published on 19 Sep 2025

Constructing Scissor+ risk model to predict prognosis and immunotherapy responses in PAAD by integrating bulk and single-cell RNA sequencing data

in Pharmacology of Anti-Cancer Drugs

Gaofei Zhang
Jiao Yu
Fan Zhang
Fang Wang
Congya Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1646840

213 views

Original Research

Published on 19 Sep 2025

Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model

in Neuropharmacology

Monserrat Fuentes-Mejia
Maximiliano J. Fallico
Alan Talevi
Luciana Gavernet
Sandra A. Orozco-Suárez
Luisa Rocha

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1644018

187 views

Original Research

Published on 19 Sep 2025

Combined opioid-sodium aescinate therapy in blunt thoracic trauma: retrospective evaluation

in Drugs Outcomes Research and Policies

Jun Zhang
Yijie Yan
Zhiyu Guan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1623916

202 views

Original Research

Accepted on 18 Sep 2025

Scutellarin attenuates hypoxia-induced retinal neovascularization through bidirectional modulation of the VEGF/Ang/Tie2 pathway

in Experimental Pharmacology and Drug Discovery

Shan Ding
Wei Wang
Chunmeng Liu
Wenfeng Zhang
Jie Wang
Fuwen Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1631316

Original Research

Accepted on 18 Sep 2025

Study on Cerebrospinal Fluid Meropenem, Vancomycin and Tigecycline Monitoring in Patients with Central Nervous System Infection Following Neurosurgery Under Different Drug Regimens

in Drug Metabolism and Transport

Xiaoman Zhao
Yanan Qiao
Qing Xie
Zheng Zhang
Yan Song
Jianbang Kang
Jinchuan Li
Jinju Duan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1666168

Review

Accepted on 18 Sep 2025

3D In Vitro Blood–Brain Barrier Models: Recent Advances and Their Role in Brain Disease Research and Therapy

in Integrative and Regenerative Pharmacology

Laura O'Halloran
Olutoyosi Akinsete
A. Leah Kogan
Michelle Wrona
Amira F Mahdi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1637602

Rational design of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors featuring 1,2,3-triazole derivatives with enhanced anti-inflammatory and analgesic efficacy

Single-versus multiple-inhaler triple therapy in patients with COPD in Spain: a retrospective cohort study comparing adherence, persistence, risk of exacerbations and economic outcomes

ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases

Research progress on plant-derived natural compounds regulating the MAPK signaling pathway for the prevention and therapy of Alzheimer’s disease

Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis

Comprehensive chemical profiling and human health risk assessment of potentially toxic heavy metals in some traditional herbal concoctions from Botswana

Exploration of the role of Fomitopsis officinalis Ames in the treatment of gastric cancer using network pharmacology, molecular docking, and in vitro experiments

Exploring the top 30 drugs associated with drug-induced thrombotic microangiopathy based on the FDA adverse event reporting system

Multidisciplinary administrative-professional-technical interventions to optimize antibiotic use and reduce resistance in a tertiary general hospital

Prevalence of risk phenotypes associated with CYP2C9*2, *3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice

Constructing Scissor+ risk model to predict prognosis and immunotherapy responses in PAAD by integrating bulk and single-cell RNA sequencing data

Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model

Combined opioid-sodium aescinate therapy in blunt thoracic trauma: retrospective evaluation

Scutellarin attenuates hypoxia-induced retinal neovascularization through bidirectional modulation of the VEGF/Ang/Tie2 pathway

Study on Cerebrospinal Fluid Meropenem, Vancomycin and Tigecycline Monitoring in Patients with Central Nervous System Infection Following Neurosurgery Under Different Drug Regimens

3D In Vitro Blood–Brain Barrier Models: Recent Advances and Their Role in Brain Disease Research and Therapy

Prevalence of risk phenotypes associated with CYP2C92, 3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice